The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

GP leaders across the country are advising practices to push back on private providers requesting input for weight-loss jab ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Retatrutide, an experimental drug by Eli Lilly, shows promising results in weight loss by targeting three hormones, ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

But with tirzepatide removed from the shortages ... The restoration of Mounjaro’s availability coincides with increasing competition in the GLP-1 space. Eli Lilly’s strategic moves to ...

"Offering Zepbound single-dose vials […] through another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved, and regulated obesity treatment ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight. At the Cardiometabolic Health Congress ...

Specializing in cutting-edge treatments like Semaglutide and Tirzepatide, Zest Meds has positioned itself as a leader in the weight loss industry. Their approach is simple yet effective ...

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...